Disease relevance of Nitraquazone

• This review mainly covers PDE 4 inhibitors structurally related to xanthines and Nitraquazone, which appear to be very attractive models for the synthesis of novel PDE 4 inhibitors potentially useful for the treatment of asthma, chronic pulmonary obstructive disease and some autoimmune diseases [1].

High impact information on Nitraquazone

• Thus, phosphorylation of PDE-4D3 induces an apparent conformation change that increases maximum velocity and sensitivity to inhibition by some analogues of nitraquazone [2].
• Additional PDE 4 inhibitors, denbufylline, Ro 20-1724, RP 73401 and nitraquazone, were all found to be effective inhibitors of mediator release in basophils but were ineffective in HLMC unless high concentrations (1 mM) were employed [3].
• The differential inhibitor effect on various leukocyte subpopulations was demonstrated by a greater sensitivity of atopic lymphocytes and T cells for nitraquazone than for Ro 20-1724 [4].

References